Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery

Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery

(2016) Bindu Thapa et al.   Acta Biomaterialia

Fibronectin-modified surfaces for evaluating the influence of cell adhesion on sensitivity of leukemic cells to siRNA nanoparticles

(2016) Juliana Valencia-Serna et al.   Nanomedicine

siRNA Versus miRNA as Therapeutics for Gene Silencing

(2015) Jenny K W Lam et al.   Molecular Therapy-Nucleic Acids

Estrogen Receptor β Isoform 5 Confers Sensitivity of Breast Cancer Cell Lines to Chemotherapeutic Agent-Induced Apoptosis through Interaction with Bcl2L12

(2015) Ming-Tsung Lee et al.   NEOPLASIA

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening

(2014) Sireesha V Garimella et al.   BREAST CANCER RESEARCH

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis

(2014) I Karl et al.   Cell Death & Disease

Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells

(2013) H M Aliabadi et al.   CANCER GENE THERAPY

Targeting SOD1 reduces experimental non–small-cell lung cancer

(2013) Andrea Glasauer et al.   JOURNAL OF CLINICAL INVESTIGATION

Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy

(2013) Hamidreza Montazeri Aliabadi et al.   JOURNAL OF CONTROLLED RELEASE

Resistance to TRAIL and how to surmount it

(2012) Danijela Maksimovic-Ivanic et al.   IMMUNOLOGIC RESEARCH

Modification of human BMSC with nanoparticles of polymeric biomaterials and plasmid DNA for BMP-2 secretion

(2012) Yufu Wang et al.   JOURNAL OF SURGICAL RESEARCH

XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells

(2012) J. L. Allensworth et al.   MOLECULAR CANCER THERAPEUTICS

Lipid substitution on low molecular weight (0.6–2.0kDa) polyethylenimine leads to a higher zeta potential of plasmid DNA and enhances transgene expression

(2011) K.C. Remant Bahadur et al.   Acta Biomaterialia

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The therapeutic potential of TRAIL receptor signalling in cancer cells

(2011) Rosario Yerbes et al.   Clinical & Translational Oncology

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines

(2011) R. Somwar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Exogenous Antioxidants—Double-Edged Swords in Cellular Redox State: Health Beneficial Effects at Physiologic Doses versus Deleterious Effects at High Doses

(2010) Jaouad Bouayed et al.   Oxidative Medicine and Cellular Longevity

Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells

(2008) Yi Hong et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma

(2008) A. H. Stegh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA